Evidence map›Paper›PMID 24373791›Full record

ReviewThe Journal of steroid biochemistry and molecular biology2014

Soy isoflavones and prostate cancer: a review of molecular mechanisms.

Abeer M Mahmoud, Wancai Yang, Maarten C Bosland

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of steroid biochemistry and molecular biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 6 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 6 syntheses or guidelines pooled it, 278 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. The logarithmic phase as a therapeutic direction: evaluating pharmacological strategies against cancer progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Genome-Wide Identification and Characterization ofInternational journal of molecular sciences · 2025
    Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Cellular and Molecular Mechanisms Modulated by Genistein in Cancer.International journal of molecular sciences · 2025
    Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Abeer M MahmoudDepartment of Pathology, University of Illinois at Chicago, Chicago, IL, USA. Electronic address: amahmo4@uic.edu.
Wancai YangDepartment of Pathology, University of Illinois at Chicago, Chicago, IL, USA; Department of Pathology, Xinxiang Medical University, Xinxiang, China.
Maarten C BoslandDepartment of Pathology, University of Illinois at Chicago, Chicago, IL, USA.
University of Illinois Chicago · USXinxiang Medical University · CN

Funding

ADJUVANT TRIAL WITH SOY AFTER RADICAL PROSTATECTOMYR01CA116195 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BOSLAND, MAARTEN C · 2006 to 2010
$1.6M
NCI NIH HHS CA 116195NCI NIH HHS R01 CA116195
6 · The paper itself

Abstract

Soy isoflavones are dietary components for which an association has been demonstrated with reduced risk of prostate cancer (PCa) in Asian populations. However, the exact mechanism by which these isoflavones may prevent the development or progression of PCa is not completely understood. There are a growing number of animal and in vitro studies that have attempted to elucidate these mechanisms. The predominant and most biologically active isoflavones in soy products, genistein, daidzein, equol, and glycetin, inhibit prostate carcinogenesis in some animal models. Cell-based studies show that soy isoflavones regulate genes that control cell cycle and apoptosis. In this review, we discuss the literature relevant to the molecular events that may account for the benefit of soy isoflavones in PCa prevention or treatment. These reports show that although soy isoflavone-induced growth arrest and apoptosis of PCa cells are plausible mechanisms, other chemo protective mechanisms are also worthy of consideration. These possible mechanisms include antioxidant defense, DNA repair, inhibition of angiogenesis and metastasis, potentiation of radio- and chemotherapeutic agents, and antagonism of estrogen- and androgen-mediated signaling pathways. Moreover, other cells in the cancer milieu, such as the fibroblastic stromal cells, endothelial cells, and immune cells, may be targeted by soy isoflavones, which may contribute to soy-mediated prostate cancer prevention. In this review, these mechanisms are discussed along with considerations about the doses and the preclinical models that have been used.

Indexed as

Angiogenesis InhibitorsAnimalsAntioxidantsApoptosisAutophagyCell CycleCell DifferentiationDNA RepairEpigenesis, GeneticGlycine maxHumansInsulin-Like Growth Factor IIsoflavonesMaleMicroRNAsNeoplasm MetastasisAngiogenesis InhibitorsAntioxidantsInsulin-Like Growth Factor IIsoflavonesMicroRNAsProstaglandinsProtein-Tyrosine KinasesRadiation-Sensitizing AgentsReceptors, AndrogenReceptors, EstrogenTransforming Growth Factor betaactivated protein kinaseadenomatous polyposis coliAPCAPE1/RefAPKapurinic apyrimidinic endonuclease redox effector factorB-cell translocation geneBTGcancer stem cellsChemopreventioncolony-stimulating factorCSCCSFdisheveledDSHECGF1endothelial cell growth factorEPHBephrin BFAKfocal adhesion kinaseGADDGenisteinglutathione peroxidaseglutathione reductaseglutathione S-transferase Pglycogen synthase kinase 3βglycogen synthase kinase-3βGM-CSFGPxgranulocyte monocyte-colony stimulating factorgrowth arrest and DNA damageGSk-3βGSK3βGSRGSTPHAThistone acetyltransferasesIsoflavoneLEFLHRHluteinizing hormone releasing hormonelymphoid enhancer factorN-benzyloxycarbonyl-Val-Asp-fluoromethyl-ketoneProstate cancerras association domain familyRASSFTAMsTRIMtripartite motif-containing proteintumor associated macrophagesuPAurokinase-type plasminogen activatorz-VAD-fmk

Identifiers

PMID24373791
PMCPMC3962012
OpenAlexW2025894464

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.